Cassava Sciences Announces Corporate Update on Alzheimer's Drug Simufilam
核心洞察
Cassava Sciences (搜索) will host a conference call and webcast on November 25th to provide a corporate update.
The update will likely cover the ongoing Phase 3 clinical trials of Simufilam for Alzheimer's disease.
Simufilam is an investigational oral small molecule drug targeting filamin A (搜索) protein.
Cassava Sciences (搜索) Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company, announced it will hold a corporate update via conference call and webcast on Monday, November 25th, at 8:00 a.m. Eastern Time. The update is expected to provide insights into the progress of Simufilam, Cassava's investigational drug for Alzheimer's disease.
Simufilam is an oral, small molecule drug candidate currently in Phase 3 clinical trials as a potential treatment for Alzheimer's disease. The drug targets the filamin A (搜索) protein, which is believed to play a role in the pathology of Alzheimer's. Cassava Sciences (搜索) retains exclusive worldwide rights to Simufilam and its related technologies.
Cassava Sciences (搜索) is focused on detecting and treating neurodegenerative diseases, with Alzheimer's disease as its primary focus. The corporate update is anticipated to cover key milestones and developments in the clinical trials of Simufilam. A replay of the audio webcast will be available on the company's website for 90 days following the live event.